Pancreatic Cancer Clinical Trial
Official title:
Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial
Pancreatoduodenectomy carries high morbidity rates even in high-volume centers.
Postoperative complications often preclude or delay adequate oral nutrition and nutritional
support may be required. However, the role of perioperative nutritional supplementation in
well-nourished patients remains controversial.
The purpose of this study is to compare the influence of early enteral and oral nutrition on
postoperative course and complications after pancreatoduodenectomy.
96 patients undergoing pancreatoduodenectomy will be randomized to receive early enteral
nutrition (EN group) or early oral nutrition (PerOs group). The EN group will receive
standard enteral diet administered through a nasojejunal tube. Enteral nutrition will be
started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated
level. The PerOs group will receive oral diets beginning from the 2nd postoperative day and
oral intake will be advanced as tolerated.
Background & aim: Pancreatoduodenectomy carries high morbidity rates even in high-volume
centers. Postoperative complications often preclude or delay adequate oral nutrition and
nutritional support may be required. However, the role of perioperative nutritional
supplementation in well-nourished patients remains controversial. There are not any standard
protocols for nutritional support after major upper gastrointestinal surgery in these
patients and postoperative nutritional regimens depend mainly upon surgeon's or center
preference.
Patients undergoing pancreatoduodenectomy often begin oral intake a week after operation and
enteral or parenteral nutrition is used to cover the daily caloric requirements during this
period, although their role still remains questionable. The safety of early oral nutrition
has been confirmed in the majority of gastrointestinal procedures. However, pancreatic
surgeons are quite reluctant to advance oral diet within the first postoperative week after
pancreatoduodenectomy due to fear of anastomosis breakdown or delayed gastric emptying
syndrome. These two postoperative nutritional regimens, early oral vs. early enteral
nutrition, have not been sufficiently evaluated in a prospective, randomized study.
Material and Methods: 96 patients undergoing pancreatoduodenectomy will be randomized to
receive early enteral nutrition (EN group) or early oral nutrition (PerOs group). The EN
group will receive standard enteral diet administered through a nasojejunal tube. The
enteral nutrition will be started on the 1st postoperative day and increased daily by 20-40
ml up to the estimated level. The PerOs group will receive oral diets beginning from the 2nd
postoperative day and oral intake will be advanced as tolerated.
Purpose: The purpose of this study is to compare the influence of early enteral and oral
nutrition on postoperative course and complications after pancreatoduodenectomy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|